Dr. Puri on the Rationale to Evaluate Real-World Multiomic Characterization of SCLC Subtypes

Partner | Cancer Centers | <b>Huntsman Cancer Institute at the University of Utah </b>

Sonam Puri, MD, discusses the rationale to evaluate the real-world multiomic characterization of small cell lung cancer subtypes.

Sonam Puri, MD, thoracic oncologist, Huntsman Cancer Institute, assistant professor, Division of Oncology, Department of Medicine, University of Utah, discusses the rationale to evaluate the real-world multiomic characterization of small cell lung cancer (SCLC) subtypes. 

SCLC is an aggressive type of lung cancer that is associated with poor patient outcomes, says Puri. Although non–small cell lung cancer (NSCLC) treatment is largely driven by biomarkers, SCLC is treated as a single disease, Puri explains. However, emerging research is confirming that, like NSCLC, SCLC can be classified into lineage-defined subtypes based on transcription factors, such as ASCL1, NEUROD1, POU2F3, and YAP1, Puri says.

Although the data are limited, the subtypes appear to have therapeutic vulnerabilities, so a larger study was conducted using the Caris Life Sciences database, Puri concludes.